AzurRx BioPharma, Inc. (NASDAQ: AZRX) Announces Encouraging Results in Phase IIa Trial for MS1819-SD
Encouraging results noted for pancreatitis patients with exocrine pancreatic insufficiency Early data shows favorable safety profile, positive dose tolerance Favorable trends observed in other identified markers Study is being performed at four sites in Australia and New Zealand New York-based AzurRx BioPharma Inc. (NASDAQ: AZRX), a biopharmaceutical company engaged in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders, recently announced positive results from its ongoing clinical trials of MS1819-SD, a recombinant lipase, developed for the treatment of exocrine pancreatic insufficiency (EPI) caused by chronic pancreatitis. In an update issued last week (http://nnw.fm/QhRk8), AzurRx…